- Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectors
- Holtz to remain on the Board of Directors of the Company and retain key elements of his executive role, including overseeing accounting, budgeting, and supporting key business operations
Gaithersburg, Maryland – September 9, 2020: — MaxCyte, Inc., a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief Financial Officer (CFO). Ron Holtz, who has served as MaxCyte’s CFO since 2005, will become Senior Vice President and Chief Accounting Officer (SVP & CAO).
Before joining MaxCyte, Ms. Murphy served as a Managing Director of BTIG, LLC. She has specialized in gene therapy, gene editing and cell therapy equity research for both burgeoning private and established public healthcare companies. Prior to BTIG, she was a Partner and Healthcare Analyst at William Blair & Company, focused on diagnostic services and life sciences. She received a BS in biology from Boston College’s honors program, and an MBA in finance, accounting and economics from the Kellogg Graduate School of Management at Northwestern University.
MaxCyte President & CEO, Doug Doerfler, said: “We are extremely pleased to welcome Amanda, who served as a successful, respected analyst in both the enabling technology and cell therapy sectors, to the MaxCyte team at this pivotal moment for the Company and the industry. We are collectively witnessing the beginning of cell and gene therapies’ impact on revolutionizing medical treatment and saving human lives, and Amanda’s wealth of experience – her deep understanding of the financial community and her unique, insightful, strategic view of the cell therapy sector – will support the continued development and expansion of MaxCyte’s contribution in this space.”
Click here to read more via BioBuzz.